← Back to Search

Monoclonal Antibodies

A Phase 2b Diabetic Kidney Disease Study

Phase 2
Waitlist Available
Research Sponsored by AstraZeneca
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 1, day 29, day 85 and day 169

Summary

This trial is testing a new drug called MEDI3506 to help adults with diabetic kidney disease. The drug aims to reduce protein in the urine and improve kidney function. It is being tested on patients who may not fully respond to standard treatments.

Eligible Conditions
  • Diabetic Kidney Disease

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 1, day 29, day 85 and day 169
This trial's timeline: 3 weeks for screening, Varies for treatment, and day 1, day 29, day 85 and day 169 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Percent Change From Baseline to Day 169 (Week 24) in UACR - Per Protocol Population
Secondary study objectives
Asymptomatic Participants Tested Positive for COVID-19 During the Study - Safety Analysis Population
Immunogenicity of MEDI3506 - PK Analysis Population
Percent Change From Baseline to Day 169 (Week 24) in UACR - Full Analysis Population
+6 more
Other study objectives
Plasma Concentration of MEDI3506 - PK Analysis Population

Side effects data

From 2023 Phase 2 trial • 609 Patients • NCT04170543
6%
Hyperkalaemia
4%
Diarrhoea
4%
Urinary tract infection
3%
Covid-19
3%
Peripheral swelling
2%
Abdominal pain upper
2%
Constipation
2%
Pruritus
2%
Muscle spasms
2%
Back pain
2%
Nasopharyngitis
1%
Cholecystitis acute
1%
Diverticulum intestinal
1%
Pneumonia aspiration
1%
Renal impairment
1%
Orthopnoea
1%
Injection site inflammation
1%
Infected dermal cyst
1%
Rash macular
1%
Troponin increased
1%
Hypertension
1%
Bile duct stone
1%
Bleeding varicose vein
1%
Colitis microscopic
1%
C-reactive protein increased
1%
Oedema peripheral
1%
Hypokalaemia
1%
Gastritis erosive
1%
Toothache
1%
Vomiting
1%
Asthenia
1%
Pharyngitis
1%
Joint effusion
1%
Pain in extremity
1%
Cellulitis
1%
Cardio-respiratory arrest
1%
Metabolic acidosis
1%
Hypovolaemia
1%
Vaccination complication
1%
Weight increased
1%
Vitamin d deficiency
1%
Restless legs syndrome
1%
Coronary artery disease
1%
Decreased appetite
1%
Sleep apnoea syndrome
1%
Drug hypersensitivity
1%
Cardiac failure
1%
Foot deformity
1%
Gastric polyps
1%
Septic shock
1%
Faecaloma
1%
Hypervolaemia
1%
Head injury
1%
Cataract
1%
Muscle fatigue
1%
Fall
1%
Abdominal pain
1%
Blood glucose increased
1%
Gastrooesophageal reflux disease
1%
Musculoskeletal chest pain
1%
Spinal stenosis
1%
Acute kidney injury
1%
Dyspnoea
1%
Dry skin
1%
Intervertebral disc degeneration
1%
Pancreatitis
1%
Folliculitis
1%
Fungal skin infection
1%
Brain natriuretic peptide increased
1%
Hypernatraemia
1%
Type 2 diabetes mellitus
1%
Hypothyroidism
100%
80%
60%
40%
20%
0%
Study treatment Arm
MEDI3506 60 mg
MEDI3506 300 mg
MEDI3506 120 mg
MEDI3506 30 mg
Placebo

Trial Design

5Treatment groups
Experimental Treatment
Placebo Group
Group I: Group 4Experimental Treatment2 Interventions
MEDI3506 Dose 4 plus Dapagliflozin (Day 85 to Day 168).
Group II: Group 3Experimental Treatment2 Interventions
MEDI3506 Dose 3 plus Dapagliflozin (Day 85 to Day 168).
Group III: Group 2Experimental Treatment2 Interventions
MEDI3506 Dose 2 plus Dapagliflozin (Day 85 to Day 168).
Group IV: Group 1Experimental Treatment2 Interventions
MEDI3506 Dose 1 plus Dapagliflozin (Day 85 to Day 168).
Group V: Group 5Placebo Group2 Interventions
Placebo (volume matched) plus Dapagliflozin (Day 85 to Day 168).
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
MEDI3506
2021
Completed Phase 2
~1270
Dapagliflozin
2014
Completed Phase 4
~64440

Find a Location

Who is running the clinical trial?

AstraZenecaLead Sponsor
4,427 Previous Clinical Trials
289,164,002 Total Patients Enrolled
~100 spots leftby Dec 2025